Shopping Cart - CHF 0.00

You have no items in your shopping cart.

  • Home  » 
  • 4039778
Return to Previous Page
4039778

Availability: In stock

Acetyl-(Nle⁴,Asp⁵,D-Phe⁷,Lys¹⁰)-cyclo-α-MSH (4-10) amide acetate salt
Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys-NH₂) acetate salt

4039778

Product No. Pack Size Available ADS InfoAnalytical Data Sheet List Price Online Order Price Qty
4039778.0001 1 mg Ships within 1 business day ADSExemplary Data Sheet of a current available lot.
CHF 105.00
CHF 97.65 (7%)
4039778.0005 5 mg Ships within 1 business day ADSExemplary Data Sheet of a current available lot.
CHF 420.00
CHF 390.60 (7%)

Details

Melanotan II, a cyclic MSH analog, is a potent full agonist of the melanocortin-3 and melanocortin-4 receptors (MC3-R and MC4-R). Intracerebroventricular administration of MTII inhibited feeding in four different mouse models of hyperphagia. MTII is a valuable tool for the study of the agouti obesity syndrome and of the role of melanocortinergic neurons in feeding.
Catalog Number H-3902
APC Number 68-1-30
Synonyms MTII, Melanotan II, Bremelanotide amide, (Ac-Nle4, Asp5, DPhe7, Lys10)-Cyclo-a-MSH (4-10) amide
Molecular Formula C₅₀H₆₉N₁₅O₉
Relative Molecular Mass 1024.19
CAS Registry Number [121062-08-6] net
Source Synthetic
Storage Conditions -20 ± 5 °C
Areas of Interest Cancer Research
Cosmetic Peptides & Dermatology
Obesity Research
Pituitary & Hypothalamic Hormones
Links / Documents:
Brochures:
No brochures found.

Bachem product citations

S.Rossi et al., Mediators Inflamm., 2016, 7368389 (2016)
A.Yavari et al., Cell Metab., 23, 821 (2016)
B.Lute et al., Cell Metab., 20, 333 (2014)
K.Nohara et al., Obesity (Silver Spring), 22, 1477 (2014)
H.Pei et al., Mol. Metab., 3, 209 (2014)
S.Veiksina et al., Biochim. Biophys. Acta, 1838, 372 (2014)
H.Cui and M.Lutter, Genes Brain Behav., 12, 658 (2013)
H.Cui and M.Lutter, Genes Brain Behav., 12, 658 (2013)
H.Cui and M.Lutter, Genes Brain Behav., 12, 658 (2013)
P.Li et al., Exp. Physiol., 98, 435 (2013)
J.W.Sohn et al., Cell, 152, 612 (2013)
Y.Xu et al., Cell Mtab., 18, 860 (2013)
S.K.Billes et al., Mol. Metab., 1, 86 (2012)
C.Blouet and G.J.Schwartz, Cell Metab., 16, 579 (2012)
C.Blouet et al., J. Neurosci., 32, 9870 (2012)
H.Cui et al., J. Comp. Neurol., 520, 4168 (2012)
Z.Wu et al., PLoS One, 7, e45167 (2012)
Y.Cao et al., PLoS One, 6, e18324 (2011)
B.G.Irani et al., Eur. J. Pharmacol., 660, 80 (2011)
A.Leckstrom et al., Life Sci., 88, 664 (2011)
A.Leckstrom et al., Neuropeptides, 45, 123 (2011)
J.C.Chuang et al., Biol. Psychiatry, 67, 1075 (2010)
J.Y.Altarejos et al., Nat. Med., 14, 1112 (2008)
J.Y.Altarejos et al., Nat. Med., 14, 1112 (2008)
D.Li and A.W.Taylor, J. Leukoc. Biol., 84, 191 (2008)
M.Claret et al., J. Clin. Invest., 117, 2325 (2007)
I.Melnick et al., Neuron, 56, 1103 (2007)
C.R.Abbott et al, Int. J. Obes. (Lond.), 30, 288 (2006)
E.U.Do et al., Biochem. Biophys. Res. Commun., 343, 1094 (2006)
Z.Xiang et al., Biochemistry, 45, 7277 (2006)
N.Balthasar et al., Cell, 123, 493 (2005)
R.L.Bradley et al., Obes. Res., 13, 653 (2005)
D.Flora et al., Bioorg. Med. Chem. Lett., 15, 1065 (2005)
D.Flora et al., Bioorg. Med. Chem. Lett., 15, 1065 (2005)
F.Giuliano et al., Eur. Urol., 48, 145 (2005)
M.Doghman et al., Endocrinology, 145, 541 (2004)
W.A.Nijenhuis et al., Eur. J. Pharmacol., 495, 145 (2004)
W.A.Nijenhuis et al., Eur. J. Pharmacol., 495, 145 (2004)
A.Wilczynski et al., J. Med. Chem., 47, 2194 (2004)
A.N.van den Pol et al., Neuron, 42, 635 (2004)
S.J.Getting et al., J. Pharmacol. Exp. Ther., 306, 631 (2003)
C.G.Joseph et al., Peptides, 24, 1899 (2003)
C.Polidori and N.Geary, Peptides, 23, 1697 (2002)
R.Thirumoorthy et al., J. Med. Chem., 44, 4114 (2001)

Product citations

W.Fan et al., Nature, 385, 165 (1997)
V.J.Hruby et al., J. Med. Chem., 38, 3454 (1995)